GRAIL To Present New Data Highlighting Galleri MCED Test Performance And Safety From Registrational PATHFINDER 2 Study At ESMO Congress 2025

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA)

Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively

MENLO PARK, Calif., Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from its registrational PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Oct. 17-21, 2025. The PATHFINDER 2 study, conducted under an FDA-approved investigational device exemption application, is the largest MCED interventional study conducted in the U.S. in an intended use population with no clinical suspicion of cancer.